Famotidine (Pepcid)
What studies of Famotidine (Pepcid) found
At a glance, by condition
Long COVID: B May help
Based on the strongest evidence, the placebo trial (low certainty), for cognition (brain fog).
3 outcomes rated · see each below
Preventing long COVID: C Might help, very uncertain
Based on the strongest evidence, the randomised trial (very low certainty): 4 findings, all C.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, Famotidine (Pepcid) may help, but the evidence is still limited. For preventing long COVID, Famotidine (Pepcid) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- Famotidine (Pepcid) · Long COVID is hereBMay helpImprovement, low certainty
- Famotidine (Pepcid) · Preventing long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Cognition (brain fog)1 study · 25 people took Famotidine (Pepcid) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (50 in all).
The placebo trial60 randomised · 50 analysed · 12 weeks · 40 mg, twice daily
Cognition (brain fog) improved more than in the comparison group.
Famotidine (Pepcid) may improve cognition (brain fog) in long COVID. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people (50 in all)
Combination: Fexofenadine (Allegra) + Famotidine (Pepcid)14 in the study
Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. (2023): Unchanged brain fog (%), no clear difference.
Shown, not counted: Famotidine (Pepcid) was given together with other treatments.
See the 1 study
-
- People in the study
- 60 randomised · 50 analysed
- Dose
- 40 mg, twice daily
- Outcome
- MMSE score at week 6 Mini-Mental State Examination
- Effect
- better
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Anxiety1 study · 25 people took Famotidine (Pepcid) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 50 people found no clear difference; a small benefit can't be ruled out.
The placebo trial60 randomised · 50 analysed · 12 weeks · 40 mg, twice daily
No clear difference in anxiety.
The evidence is very uncertain about the effect of famotidine (Pepcid) on anxiety in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 50 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 60 randomised · 50 analysed
- Dose
- 40 mg, twice daily
- Outcome
- Ham-A score at week 6 Hamilton Anxiety Rating Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Depression1 study · 25 people took Famotidine (Pepcid) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 50 people found no clear difference; a small benefit can't be ruled out.
The placebo trial60 randomised · 50 analysed · 12 weeks · 40 mg, twice daily
No clear difference in depression.
The evidence is very uncertain about the effect of famotidine (Pepcid) on depression in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 50 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 60 randomised · 50 analysed
- Dose
- 40 mg, twice daily
- Outcome
- Ham-D score at week 6 Hamilton Depression Rating Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Preventing long COVID
Symptoms
Breathlessness1 study · 138 people took Famotidine (Pepcid) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (275 in all).
The randomised trial275 randomised · 10-days · for 10-days
Breathlessness improved more than in the comparison group.
The evidence is very uncertain about the effect of famotidine (Pepcid) on breathlessness later, when given during acute COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (275 in all)
See the 1 study
-
- People in the study
- 275 randomised
- Dose
- for 10-days
- Outcome
- fatigue and nasal symptoms at day-14
- Effect
- better (not tested)
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Fatigue1 study · 138 people took Famotidine (Pepcid) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (275 in all).
The randomised trial275 randomised · 10-days · for 10-days
Fatigue improved more than in the comparison group.
The evidence is very uncertain about the effect of famotidine (Pepcid) on fatigue later, when given during acute COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (275 in all)
See the 1 study
-
- People in the study
- 275 randomised
- Dose
- for 10-days
- Outcome
- fatigue and nasal symptoms at day-14
- Effect
- better (not tested)
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Overall symptoms1 study · 138 people took Famotidine (Pepcid) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (275 in all).
The randomised trial275 randomised · 10-days · for 10-days
Overall symptoms improved more than in the comparison group.
The evidence is very uncertain about the effect of famotidine (Pepcid) on overall symptoms later, when given during acute COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (275 in all)
See the 1 study
-
- People in the study
- 275 randomised
- Dose
- for 10-days
- Outcome
- Symptoms of early long-COVID
- Effect
- better (not tested)
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Quality of life1 study · 138 people took Famotidine (Pepcid) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (275 in all).
The randomised trial275 randomised · 10-days · for 10-days
Quality of life improved more than in the comparison group.
The evidence is very uncertain about the effect of famotidine (Pepcid) on quality of life later, when given during acute COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (275 in all)
See the 1 study
-
- People in the study
- 275 randomised
- Dose
- for 10-days
- Outcome
- WHO-5-wellbeing-scores
- Effect
- better (not tested)
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Studies of combinations
Outcomes that only studies of Famotidine (Pepcid) given together with other treatments looked at. Shown, not graded: they can’t tell what Famotidine (Pepcid) did alone.
Daily functioning Both together
Combination: Physical therapy / physiotherapy + Cycling + Jogging and running + Salt, electrolytes and fluids + Compression garments + Fludrocortisone / Florinef + Midodrine + Atenolol (Tenormin) + Mestinon / pyridostigmine + Ivabradine + Clonidine + Methylphenidate (Ritalin, Concerta) + Fexofenadine (Allegra) + Famotidine (Pepcid) + Cromolyn (Gastrocrom, Nalcrom) + Baicalein and quercetin + Escitalopram (Lexapro) + Low-dose naltrexone1 in the study
A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023): activity tolerance competing in cross country event, better (not tested).
Shown, not counted: Famotidine (Pepcid) was given together with other treatments.
Fatigue Long COVID
Combination: Famotidine (Pepcid) + Loratadine (Claritin)778 randomised · 668 analysed
Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. (2026): 12-week FAS score, better.
Shown, not counted: Famotidine (Pepcid) was given together with other treatments.
Combination: Fexofenadine (Allegra) + Famotidine (Pepcid)14 in the study
Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. (2023): Unchanged fatigue (%), better.
Shown, not counted: Famotidine (Pepcid) was given together with other treatments.
Quality of life Long COVID
Combination: Famotidine (Pepcid) + Loratadine (Claritin)778 randomised · 668 analysed
Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. (2026): EQ-VAS score at 12 weeks, better.
Shown, not counted: Famotidine (Pepcid) was given together with other treatments.
Overall symptoms Long COVID
Combination: Fexofenadine (Allegra) + Famotidine (Pepcid)14 in the study
Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. (2023): Long-COVID (%), no clear difference.
Shown, not counted: Famotidine (Pepcid) was given together with other treatments.
Autonomic symptoms Long COVID
Combination: Fexofenadine (Allegra) + Famotidine (Pepcid)14 in the study
Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. (2023): Increased HR (%), better.
Shown, not counted: Famotidine (Pepcid) was given together with other treatments.
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
40 mg at the start
- 2Top dose
Most often 40 mg (3 of 3 studies)
Doses across 3 studies
40 to 40 mg.
Each study’s dose, as printed
- 40 mg, once daily Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. (2026)
- 40 mg once daily, at bedtime Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. (2023)
- 40 mg, twice daily Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study. (2023)
All papers
- Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study.2023 · placebo trial · 60 randomised · 50 analysed
Summary
This randomized, placebo-controlled, double-blind study enrolled 60 patients with cognitive and behavioral dysfunctions after COVID-19 at a tertiary COVID-19 care center in Tehran. The abstract states 50 patients were randomly assigned, while the results state 60 were enrolled and randomized. Patients received famotidine 40 mg twice daily or placebo for 12 weeks, with outcomes at baseline, week 6, and week 12. Fifty patients were included in the intention-to-treat population (25 famotidine, 25 placebo). Ten patients (five per arm) dropped out before the first clinical assessment; 45 completed the trial, and five (two famotidine, three placebo) dropped out between weeks 6 and 12 due to commuting problems. At week 6 and week 12, MMSE scores were higher in the famotidine group (p = 0.014 and p < 0.001), and MoCA scores were higher (p = 0.001 and p < 0.001). HAM-D reductions were larger in the famotidine group at week 6 (p = 0.009) and week 12 (p = 0.02); HAM-A reductions were larger at week 6 (p = 0.042) and week 12 (p = 0.027). Side effects reported in both groups with mild severity included nausea, dizziness, weakness, insomnia, diarrhea, fatigue, headache, and constipation; the paper reports no significant difference in frequency of adverse effects between groups and no unexpected adverse effect. The authors state limits including a 12-week follow-up, a modest sample size, and no primary/secondary outcome delineation in the registration.
- Therapies to prevent progression of COVID-19, including Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc with or without Famotidine: a randomised controlled double-blind multi-centre outpatient cohort study2025 · randomised trial · 275 randomised
Summary
This randomised controlled multi-centre cohort study assessed a combination of repurposed drugs and supplements in early therapy of acute non-hospitalised COVID-19. Participants were over 40-years-old and positive for COVID-19 within 4 days of illness onset and received telehealth outpatient care. A total of 275 participants, vaccinated (n=151) or unvaccinated (n=124), were randomised into group-1 (n=137) or group-2 (n=138). Group-1 received ivermectin, doxycyline, zinc, vitamin-C and vitamin-D3 as core-therapy; group-2 received core-therapy plus famotidine; both for 10-days. Symptoms were reported daily until day-10, and at days 14, 28 and 90. Only 1.5% (n=4) participants were hospitalised within the first 28 days. No viral rebound was experienced by any participants who took the 10-day therapy. Symptoms of early long-COVID and WHO-5-wellbeing-scores were explored at day-90 and were reported more favourably in the famotidine arm. The abstract reports less fatigue and nasal symptoms at day-14 with the addition of famotidine. The abstract does not report the number analysed, withdrawals, or limitations.
- A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome.2026 · case report · 5 in the study
Summary
This retrospective case series described five patients from the authors' clinic with ME/CFS and mast cell activation syndrome; Case 5 also met criteria for Long COVID. The series was not a random sample or a consecutive series. Patients were instructed to take oral cromolyn as a continuous regimen, placing the day's dose in water and sipping it, and to increase from an ineffective 800 mg daily dose to 1600-2400 mg daily until optimal effect. Follow-up by case was 30, 42, 12, 24, and 22 months. Outcomes included a 0-to-100 Wellness score and symptom reports. The authors reported that all five patients benefited from a dose higher than usual and customary recommendations. Wellness scores changed from 20/100 to 70/100 (Case 1), 26/100 to 61/100 (Case 2), 30/100 to the 70-80/100 range (Case 3), and 60/100 to 86/100 (Case 4); Case 5 had no baseline or follow-up wellness value. Symptom improvements included energy, orthostatic stress, rashes, hives, flushing, gastrointestinal symptoms, fatigue, brain fog, steps, and activity. Harms included no side effects in Cases 1 and 5, worsening on lower doses of 400-800 mg daily in Case 1, severe bowel cramps and diarrhea after a missed dose in Case 2, and a wellness decline after a cromolyn shortage in Case 5. The authors noted no evidence of toxicity.
- Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways (STIMULATE-ICP) - COV-LT2-00432026 · combination: given with other treatments
- Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial.2026 · combination: given with other treatments · 778 randomised · 668 analysed
Summary
This multisite, open-label, randomised controlled trial asked whether repurposed drugs reduce fatigue in adults with long COVID who had not been hospitalised with COVID-19. It took place across 12 UK NHS specialist long COVID care clinics. 778 participants were randomly assigned 1:1:1:1 to colchicine 500 μg twice daily (n=192), famotidine 40 mg with loratadine 10 mg once daily (n=193), rivaroxaban 10 mg once daily (n=197), or no drug (n=196) for 12 weeks; all received usual care. The primary measure was the Fatigue Assessment Scale (FAS, 10 to 50, higher worse) at 12 weeks, with a 24-week FAS secondary endpoint. 668 participants had a calculable 12-week FAS score (160 colchicine, 174 famotidine–loratadine, 171 rivaroxaban, 163 no drug). Mean FAS fell within every group: 4.4 points with colchicine, 4.8 with famotidine–loratadine, 4.4 with rivaroxaban, and 3.3 with no drug. Adjusted differences versus no drug were –1.49 points (95% CI –2.92 to –0.06; p=0.041) for colchicine, –1.48 (–2.88 to –0.08; p=0.038) for famotidine–loratadine, and –1.06 (–2.47 to 0.35; p=0.139) for rivaroxaban. At 24 weeks, differences were –0.043 (p=0.96), 0.34 (p=0.66), and 0.04 (p=0.96). EQ-VAS at 12 weeks was higher by 4.13, 4.84, and 3.5 points in the colchicine, famotidine–loratadine, and rivaroxaban groups. Adverse events were reported by 57 of 192, 51 of 193, 70 of 197, and 21 of 196 participants; ten serious adverse events occurred in eight participants, five in three rivaroxaban participants. The authors state limitations including inability to exclude placebo effects or expectation bias in the open-label trial.
- A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.2023 · combination: given with other treatments · 1 in the study
Summary
This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.
- S4292 Mast Cell Activation: A Proposed Mechanism Linking Long-COVID-19 Infection and New Gastrointestinal Symptoms2023 · combination: given with other treatments · 1 in the study
Summary
This case study described one 44-year-old woman with long-COVID and new gastrointestinal symptoms. She presented with heartburn and epigastric pain for 4 months after a COVID-19 infection. Esophagogastroduodenoscopy showed normal esophagus, stomach, and duodenum; biopsies showed normal esophageal tissue and chronic inactive gastritis without Helicobacter pylori, and special staining showed scattered CD117 positive mast cells in gastric biopsies. Omeprazole was discontinued, and she was started on famotidine, an H2 antagonist, along with montelukast, a leukotriene inhibitor. Over several months, her symptoms gradually improved and eventually resolved with this regimen. There was no comparison group. The authors did not report harms or withdrawals. The authors state that gastroenterologists should be aware of mast cell activating disorders in patients with new GI symptoms after COVID-19, and that further research is needed to elucidate the relationship between mast cell activation post-COVID-19 and gastrointestinal symptoms. Limitations: no controlled comparison; the authors call for further research.
- Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation.2023 · combination: given with other treatments · 14 in the study
Summary
This retrospective study evaluated 14 patients with long-COVID symptoms attributed to mast cell activation (MCA) and 13 untreated controls. The 14 treated patients were selected from 373 people with long-COVID who were treated with H1 and H2 receptor blockers. Treated patients received fexofenadine 180 mg once daily before dinner and famotidine 40 mg once daily at bedtime for 20 days; controls were not treated with antihistamines. Fatigue, brain fog, increased heart rate, and abdominal disorders were assessed at baseline and 20 days later; symptoms were self-reported except increased heart rate, which was assessed by a physician. Long-COVID symptoms disappeared completely in 29% of treated patients. Among treated patients, fatigue fully vanished in six patients (43%), brain fog disappeared in six patients (43%), increased heart rate was no longer present in eight patients (57%), and abdominal disorders disappeared in eight patients (57%). At 20 days, long-COVID was present in 71% of treated versus 100% of untreated patients (p=0.0977). Unchanged fatigue was 21% versus 85% (p=0.0018); unchanged brain fog 43% versus 70% (p=0.2518); increased HR 29% versus 85% (p=0.0063); abdominal disorders 14% versus 62% (p=0.0183). Among controls, no symptom showed significant improvement and no symptoms disappeared. No adverse effects due to treatment were observed, and neither patients nor controls showed worsening of any symptoms. Authors state limitations including retrospective design, self-reported symptoms except heart rate, no validated questionnaires, and initial clinical choice of antihistamines only in patients with symptoms attributed to MCA.
- Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.2024 · systematic review
Summary
This qualitative systematic review asked which treatments have been studied for cognitive impairment after COVID-19. The search covered PubMed, Scopus, and ProQuest up to December 31, 2023, and included 29 studies of post-COVID cognitive impairment; samples ranged from single patients to larger groups. Treatments included cognitive remediation, multidisciplinary rehabilitation, noninvasive brain stimulation, hyperbaric oxygen, pharmacological and nutraceutical agents, neurofeedback, photobiomodulation, and meditation. Comparisons, where reported, included control, sham, placebo, or usual-care groups. Cognitive functioning was assessed with standardized tests, test batteries, or structured interviews. Findings varied. A randomized sham-controlled HBOT trial in 37 subjects reported significant improvements in global cognitive functioning, attention, and executive functions versus control. A famotidine RCT reported significantly improved global cognition in the treatment group (N = 25). A donepezil RCT found no differences between N = 15 and N = 10 in memory after 4 and 12 weeks. A tDCS randomized sham-controlled trial in 23 subjects found no significant effects on executive functioning and processing speed after eight tDCS sessions. A remote multidisciplinary RCT found no significant differences between N = 52 and N = 48. A multidisciplinary study in 80 subjects found no significant improvements in memory and attention at discharge. Other studies reported improvements in smaller or uncontrolled samples. No worsening, stopping, or side effects were reported in the recorded data. The authors state limitations including heterogeneity, lack of long-term follow-up, and under-characterization of samples.
- The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.2026 · review
Summary
This review examined pharmacological interventions for post-COVID syndrome (PCS) predominantly characterised by persistent fatigue, with no participants of its own. It summarised studies of CoQ10 plus ALA, cacao flavonoids, amantadine, L-arginine plus vitamin C, fluvoxamine, astragalus root extract, Myelophil/MYPplus, Paxlovid, abrocitinib, upadacitinib, AXA1125, oxaloacetate, nicotinamide riboside, fexofenadine plus famotidine and IVIg. In a prospective observational study, 174 people with long COVID were enrolled and 116 received CoQ10 plus ALA; 53.5% had a complete FSS response versus 3.5% in the control group, and the non-response rate was 9.5% versus 25.9%. A cacao flavonoid trial (n = 46) reported improvements after 90 days. An open-label amantadine trial enrolled 83 patients; after 2 weeks scores were significantly superior to control (P < 0.001). A single-blind trial in 46 patients reported fatigue in 8.7% with L-arginine plus vitamin C versus 80.1% with placebo at day 28 (p < 0.0001). A fluvoxamine trial enrolled 399 patients and reduced FSS scores at day 60 and day 90; the fluvoxamine group had a lower incidence of adverse events, with rare serious adverse reactions. An astragalus trial reported chronic fatigue prevalence falling from 100% to 13.8%, and 17.2% one month later, versus 80.0% and 70.0% with placebo (P < 0.0001). A phase IIa AXA1125 trial found no overall differences in objective mitochondrial function between treatment and placebo. Amantadine was well tolerated with no notable safety concerns; astragalus had no obvious adverse reactions. Current evidence is mainly from observational studies or small-sample RCTs and is insufficient as definitive evidence of efficacy.
- Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities.2026 · review
Summary
This narrative review used pragmatic methods and searches up to January 2025 to map candidate treatments for long COVID that clinicians and people with lived experience prioritised. No participant total for the review itself was reported. Evidence was summarised across intervention groups. A moderate-quality RCT of 155 participants found no significant improvement with Paxlovid. In a non-randomised controlled trial of fexofenadine plus famotidine, 14 patients were in the treatment group and 13 in the control group; 29% of treated patients had complete resolution of long COVID symptoms, and all treated patients showed significant improvement in fatigue, brain fog, abdominal disorders, and increased heart rate compared with controls. A single case report found eight out of 12 reported improved cognitive abilities with guanfacine plus N-acetylcysteine; four patients discontinued therapy, two for unspecified reasons and two due to hypotension and/or dizziness. A pilot RCT of 13 participants found active taVNS (n = 8) improved fatigue, mood, and cognitive symptoms compared with sham (n = 5), with no serious adverse events observed. A small RCT found no significant differences with 700 mg leronlimab. Two RCTs did not report any benefit from CoQ10. A case study of 4 participants reported symptom improvements up to 6 months after nicotine patches 7.5 mg per day for 7 days. Five RCTs reported multicomponent interventions improved quality of life and dyspnoea, with no strong evidence for other symptoms; 16 RCTs examined exercise training.
- A Narrative Review of the Efficacy of Long COVID Interventions on Brain Fog, Processing Speed, and Other Related Cognitive Outcomes.2025 · review
Summary
This narrative review asked which interventions have been studied for long COVID-associated neurocognitive deficits. It searched PubMed, Embase, and Scopus and included Twelve studies. Reports covered cognitive training, rTMS, exercise rehabilitation, antihistamines (fexofenadine and famotidine), Brainmax, PEA-LUT, aromatherapy, and CICT. For rTMS, one case study (n = 1) reported improved processing speed and perceptual reasoning scores; a case series (n = 4) reported that 3 of 4 participants improved on behavioral inhibition; a pilot case series (n = 23) reported a statistically significant increase in attention/concentration, memory, and planning/organizational abilities; and a case series (n = 12) reported a statistically significant increase in all four cognitive areas and FSIQ from 94.6 ± 10.9 to 104.4 ± 13.0. The REGAIN trial (585 adults; n = 298 intervention, n = 287 usual care) reported statistically significant improvement in health-related quality of life at 3 months and 12 months and in depression, fatigue, and sleep disturbance, but not in cognitive function at 12 months. Salvucci and colleagues (14 experimental, 13 control) reported that 43% of the experimental group reported vanishing of fatigue and 43% reported vanishing of brain fog; the control group reported no statistically significant improvements across symptoms. Brainmax versus placebo (15 and 15) showed a statistically significant reduction in MFI-20 scores and a slight increase in MoCA scores. CICT (n = 14; 80% of unemployed before CICT returned to work) reported improvements. Authors state limitations include absence of control group, low sample sizes, and no reported effect size calculations. Worsening, stopping, and side effects were not reported.
- Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
Summary
This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.